Enjoy a cashless check-out when you select health screening and vaccination services online. Select now.

Return to previous page

Dengue Vaccination for Ages 12-45 (3 doses) with Consultation

$529.65

Dengue is affecting 5x more Singaporeans in 2019, compared to previous years.

Just within Singapore, more than 11,000* people have caught dengue fever since January this year. This is already 5,000 more cases than the combined total of 2018 and 2017.

Why is dengue a major health concern?

If the spread of dengue is not controlled, having more infected people increases the chance of transmission to even more people -- a dangerous health hazard to the community.

On an individual level, dengue victims typically suffer from:

  • persistent symptoms such as weakness and headache, for up to 6 months
  • having to stay in bed for more than a week, feeling nauseous
  • unable to go to work/school for up to 10 days
  • in some cases, there is a more life-threatening form of dengue, called Severe/haemorrhagic dengue.

Severe dengue

Prior dengue infection does not confer protection from future dengue infections. In fact, if you have a prior infection with the dengue virus, you have an increased risk of Severe/Haemorrhagic dengue and Dengue Shock Syndrome.

Severe Dengue symptoms include: severe abdominal pain, persistent vomiting, bleeding from your gums or nose, blood in your urine, stools or vomit, bleeding under the skin, which might look like bruising, difficult or rapid breathing, cold or clammy skin, fatigue, irritability or restlessness.

Who is eligible for the vaccination?

Only people from12-45 years of age, with evidence of previous dengue infection. (blood test or verifiable medical records showing positive results for dengue antibodies).

A Pre-vaccination dengue screening test can be taken assess if there has been previous infection if you are uncertain of your prior dengue infection status.

Available here : Dengue Pre-vaccination Blood Test.

How does Vaccination benefit people who are eligible?

The dengue vaccine(Dengvaxia) has been tested in large scale clinical safety and efficacy trials, involving 40000 people from 15 countries. (between ages 12-45). The results have shown a clear, durable benefit lasting 5 years:

The Health Sciences Authority approved the use of Dengvaxia in Singapore.

Price is applicable for three doses only and includes practice cost and doctor’s consultation charge at first visit.

Applicable at selected Raffles Medical (Singapore) clinics:

  • Singapore Land Tower
  • REMC (Raffles Hospital)
  • Causeway Point
  • Jurong East
  • Tampines 1
  • Compass One
  • Ang Mo Kio
  • Lot 1 Shoppers' Mall
  • Changi Airport Terminal 3 B2
  • Siglap Centre

Terms and conditions apply.
Upon purchase, we will send to your email a redemption letter that you can use to redeem your vaccination. Please refer to your redemption letter to select your preferred clinic prior to your visit and present the same letter, and your blood test results on the day of your vaccination. Price is in Singapore dollars and inclusive of GST.

*as of Aug numbers, data from National Environment Agency (NEA)

Free Shipping for orders $50 and above
-
+
NEW
Description

Precautions to note:

  • Those with allergic reaction to any vaccine component, a previous dose, or neomycin should not have it.
  • Pregnant women should not receive the vaccine.
  • Pregnancy should be avoided until 3 months after vaccination.
  • It is not recommended for those who are immunocompromised.
  • Those with suspected egg allergy should consult the doctor before having it.

Terms and Conditions

  • Price is in Singapore dollars and inclusive of GST.
  • Price includes practice cost and doctor’s consultation charge.
  • Upon purchase, we will send to your email, a redemption letter, that you can use to redeem your vaccination. This letter can only be used for the package indicated.
  • This letter must be presented upon registration at the clinic, together with your NRIC / Identification documents.
  • Applicable at selected Raffles Medical (Singapore) clinics.
    • Singapore Land Tower
    • REMC (Raffles Hospital)
    • Causeway Point
    • Jurong East
    • Tampines 1
    • Compass One
    • Ang Mo Kio
    • Lot 1 Shoppers' Mall
    • Changi Airport Terminal 3 B2
    • Siglap Centre
  • Please refer to your redemption letter to select your preferred clinic to book your vaccine.
  • Items in the package are non-exchangeable and non-refundable, including unutilised portion.
  • You may not transfer the package to another person.
  • Not valid with other corporate programmes.
  • Listed terms are subject to change without prior notice.
  • Raffles Medical Group Ltd is not responsible for any loss or unauthorised use of the redemption letter.

What is dengue?

Dengue is a viral disease spread by Aedes mosquitoes, which can be painful and life-threatening. It is common in tropical regions, including Singapore.

 

Dengue is a national health concern, with a surge of cases in 2019

Year Total Dengue Cases
2017 2772
2018 3285
2019 (until 17August2019) 10277

 

How does dengue affect humans ?

  • Need for hospitalization
  • Loss of work productivity
  • Abscence from school
  • Significant costs incurred due to time spent in hospital and off work
  • Extreme tiredness that lasts from 2-6 months

 

What are the symptoms of dengue fever?

Second-time infection has a higher chance to lead to severe/haemorrhagic dengue, which is life-threatening.

Half a million people around the world are hospitalized for devere dengue every year, of which, 12500 die.

 

Fortunately, there is now a vaccine for dengue


12-45 years
Dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 12 to 45 years of age living in enedmic areass.

3-dose schedule
The vaccination schedule consists of three injections of 0.5ml to be administered subcutaneously at 6 months intervals
  • Vaccination recommended only in individuals with prior dengue infection.
  • Immune respose begins from dose 1*, however 3 doses are required for optimal protection
  • For individuals not previously infected by dengue virus, vaccination should not be recommended
  • Previous infection by dengue virus can be substantiated through serotesting or medical history

 

Who is suitable for dengue vaccination?

Anyone between the ages of 12-45, who has a previous episode of dengue infection (including asymptomatic cases). Pre-vaccination - an antibodies test can be taken to assess if there has been previous infection.

 

How many doses are required?

The vaccination regime requires three doses to be given over a period of 12-months, at month 0, 6 and 12.

 

How has Dengvaxia proven to be effective?

Clinical Program

Dengvaxia has been evaluated in studies involving > 40,000 people from 15 countries with up to six years of follow-up from large-scale clinical safety and efficacy investigations.1

The pivotal phase III large scale efficacy and safety trials were conducted in 10 endemic countries.

* Based on comparable immunogenicity profiles in adult populations and the phase III population, a similar level of protection by Dengvaxia® can be expected in individuals up to 45 years of age. Dengvaxia is approved in Singapore for 12 to 45 years old with past dengue infection. Please refer to the full Product Inform ati on before prescribing Dengvaxia ®

1. Sanofi Pasteur. Press Release . D engvaxia ® vaccine approved for prevention of dengue in Europe. 19 Dec 2018. Available at https://www.sanofipasteur.com/en/media room/press releases/dengvaxia vaccine approved for prevention of dengue in europe . Last accessed Aug 2019. 2. Villar L et al. N Engl J Med 2015;372(2):113 123. 3. Capeding MR, et al. Lancet 2014;384(9951):1358 1365 .

Dengvaxia efficacy in previously infected individuals1,2

Pooled efficacy analysis in 2,323 subjects 9-16 years of age who were seropositive at baseline during the 25 month active phase

  • A clear, durable benefit of vaccination up to 5 years following the first injection in hospitalized and severe dengue cases was shown2-4

1. H adinegoro SR et al. N Engl J Med 2015;373:1195 1206 2. Dengvaxia Prescribing Information for Singapore. 3. WHO. Revised SAGE recommendation on use of dengue vaccine. 19 April 2018. Available at here Last accessed Aug 2019. 4. Dear Doctor Letter “Important Findings From A Supplementary Exploratory Study On Dengvaxia® To Assess Long Term Safety And Efficacy Of Dengvaxia® From Phase IIb/III Studies” 30 Nov 2018 . S anofi Pasteur.

Dengvaxia: The vaccine against severe dengue

Pooled results during the 25 month active phase of the phase III clinical trials (VE % [95% CI])†‡1 4

  • † The efficacy of the vaccine is considered significant if the lower boundary of the 95% CI is greater than 0.
  • ‡ Pooled efficacy analysis from the two large scale efficacy trials (CYD14 and CYD15) in subjects 9 16 years of age during the 2 5 month active phase in the ITT population.

Sources :

  1. https://www.channelnewsasia.com/news/singapore/dengue-fever-singapore-clusters-highest-number-weekly-cases-june-11638610#cxrecs_s
  2. https://www.nea.gov.sg/dengue-zika/dengue/dengue-cases
Additional Information
Benefits General Well Being